Yifan Pharmaceutical (002019.SZ): N-3C01 injection approved for clinical trials

Zhitong Finance App News, Yifan Pharmaceutical (002019.SZ) announced that Hefei Xinzhu Biotechnology Co., Ltd. (“Hefei Xinzhu”), a wholly-owned subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing that Hefei Xinzhu will conduct clinical trials to treat advanced solid tumors and treat non-muscle-invasive bladder cancer (NMIBC). N-3C01